PHP
UBX

Parkman Healthcare Partners’s Unity Biotechnology UBX Stock Holding History

Parkman Healthcare Partners’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-42,749
Closed -$117K – 96
2022
Q4 		$117K Buy
42,749
+2,340
+6% +$6.8K 0.03% 80
2022
Q3 		$160K Buy
+40,409
New +$255K 0.05% 89

Other funds holding UBX

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
MC
Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return
AWA
Arete Wealth Advisors Chicago, Illinois $3.05B AUM 42.78% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Parkman Healthcare Partners's UBX Position: Q1 2023 in Review

Parkman Healthcare Partners sold out of Unity Biotechnology (UBX) in Q1 2023, closing a stake of 42,749 shares — an estimated $117K sold.

Parkman Healthcare Partners first reported a position in UBX in Q3 2022 and held it in 2 quarters. The position peaked at $160K in Q3 2022. 46 funds tracked by Wall St. Rank hold UBX as of Q1 2023.

  • Parkman Healthcare Partners reported no remaining Unity Biotechnology position as of Q1 2023 after selling out during the quarter.
  • Parkman Healthcare Partners sold 42,749 Unity Biotechnology shares in Q1 2023, an estimated $117K.
  • Parkman Healthcare Partners first reported a position in Unity Biotechnology in Q3 2022 and held it in 2 quarters.
  • Parkman Healthcare Partners's Unity Biotechnology position peaked at $160K in Q3 2022.
  • 46 funds tracked by Wall St. Rank held Unity Biotechnology as of Q1 2023.

Based on Parkman Healthcare Partners's 13F filing for Q1 2023, filed 12 May 2023.